19.4 C
New York
Wednesday, June 29, 2022

Let’s find out what exactly is happening with CRDF stock?

Cardiff Oncology (CRDF) stock is fluctuating at the moment. On Friday, March 12, 2021, it gained only 1.50% but lost 5.90% in the after-hours session. In the pre-market session of Monday, it has gained 1.50% as of this writing. There is also no latest development in the market about the CRDF.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Recent Business Activities of CRDF

Participation in Oppenheimer Investor conference

On March 11, 2021, CRDF announced that the chief executive officer of Cardiff Oncology, Dr. Mark Erlander will present and participate in one-on-one investor meetings at the Oppenheimer 31st Annual Healthcare Conference taking place March 16-18, 2021.

Participation in AACR Annual Meeting 2021

OnMarch 10, 2021, CRDF announced the publication of two abstracts. CRDF will presentthose new abstracts as electronic posters during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting 2021which will take place virtually from April 10-15, 2021.

Details on the electronic posters and corresponding abstracts are shown below.

Abstract 1Title: Expanded access program of the PLK1 inhibitor onvansertib for treatment of patients with KRAS-mutant metastatic colorectal cancer
Session Type: E-Poster Session
Session Category: Clinical Research (Excluding Trials)
Session Title: Clinical Outcomes Research
Abstract Number: 425

Abstract 2 Title: The selective polo-like kinase (Plk1) inhibitor onvansertib and the antiandrogen abiraterone synergistically kill cancer cells through disruption of mitosis independently of androgen receptor signaling
Session TypeE-Poster Session
Session Category: Experimental and Molecular Therapeutics
Session Title: Cell Cycle Mechanisms of Anticancer Drug Action
Abstract Number: 973

Participation in H.C. Wainwright Global Life Sciences Conference

CRDF participated in H.C. Wainwright Global Life Sciences Conference held on March 9-10, 2021. The Cardiff Oncology’s presentation is available on-demand at the H.C. Wainwright conference portal. The CRDF also met with the investors during the conference.

Recent Financial Results

The CRDF announced its fourth quarter and full-year 2020 financial results on February 25, 2021

  • Cardiff Oncology had approximately $131 million in cash and cash equivalents as of December 31, 2020.
  • CRDF used $5.1 million net cash in operating activities for the fourth quarter.
  • R&D expenses were $3.2 million for the reported quarter.
  • Selling, general and administrative expenses were $3.4 millionfor the reported quarter.

About Cardiff Oncology, Inc.

Cardiff Oncology was founded in 1999, and its headquarter is based in California, United States.CRDDF is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the most significant medical need.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam